BREAKING🔔 The 53th paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We elucidated the virological characteristics of SARS-CoV-2 NB.1.8.1. Please repost🔥 1/
thelancet.com/journals/lanin… NB.1.8.1 is a descendant strain of XDV (XDV is a recombinant of XDE, FL.13.4 and JN.1) and is currently spreading in Asian countries. 2/

BREAKING🔔 The 50th🎉 paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases
@TheLancetInfDis. We elucidated the virological characteristics of SARS-CoV-2 LP.8.1. Please repost🔥 1/
thelancet.com/journals/lanin… In spike, LP.8.1 has 9 mutations (S31del, F186L, R190S, R346T, V445R, F456L, Q493E, K1086R, and V1104L) compared with JN.1; and 8 amino acid residues (T22N, S31del, F59S, F186L, R190S, R346T, H445R, and K1086R) differ between the spike proteins of LP.8.1 and XEC. 2/

#拡散希望 速報🔔 G2P-Japan🇯🇵の新しいプレプリント「JN.1対応mRNAワクチンが誘導する中和抗体の効果の評価」を、bioRxiv @biorxivpreprint に発表しました。1/
biorxiv.org/content/10.110… 本研究では、#ファイザー 🇺🇸🇩🇪のワクチンと、#第一三共 🇯🇵の国産ワクチンを接種した方の、ワクチン接種前後の血清を用いた検討実験を行いました。
まず朗報として、２つのワクチンで誘導される中和抗体の活性に大差はなく、どちらの血清も、JN.1のみならずKP.3.1.1やXECの感染を強く抑制しました。2/

BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Keiya @Keiya717, is out at @biorxivpreprint. We assessed the humoral immunity induced by JN.1 mRNA vaccines against a broad range of SARS-CoV-2 variants including JN.1, KP.3.1.1 & XEC. Please repost🔥 1/
biorxiv.org/content/10.110… In this study, we used 2 mRNA vaccines, one is from Pfizer/BioNTech🇺🇸🇩🇪, while another is from Daiichi-Sankyo🇯🇵. The good news is that there are no significant differences between them and both broadly neutralized a variety of SARS-CoV-2 including JN.1, KP.3.1.1 and XEC. 2/

BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Yu in my lab, is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 #XEC. Please repost🔥 1/
biorxiv.org/content/10.110… Compared with KP.3, #XEC harbors two spike substitutions, S:T22N and S:F59S. Recombination analysis by Shusuke @KawakuboShusuke showed that XEC is a recombinant lineage of KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3) with a breakpoint at genomic position 21,738–22,599. 2/

#拡散希望 速報🔔 G2P-Japan🇯🇵の新しい研究成果「新型コロナウイルス変異株KP.3.1.1のウイルス学的特性の解明」について、プレプリント公開に先立って速報します。本研究では、最近いくつかの国で増加傾向にある、JN.1の子孫株である新しい変異株KP.3.1.1の特性を検証しました。1/ 春になり、JN.1の子孫株が出現し、それらが優勢になり始めています。現在本邦は第11波に入っていますが、それはこれらのJN.1の子孫株によって引き起こされています。現在の流行状況などについては、本日公開の最新コラムで解説しています↓ 2/

https://x.com/SystemsVirology/status/1813355447442891090

BREAKING🔔 Here I want to quickly report our new results from G2P-Japan🇯🇵 before the preprint publication. We have elucidated the virological characteristics of SARS-CoV-2 KP.3.1.1 - a progeny of JN.1. Please RT🔥 1/ Cf.1 A new one, KP.2 (JN.1.11.1.2), has been already elucidated. 2/

https://x.com/G2PJapan/status/1793071073006866929

#拡散希望 速報🔔 G2P-Japan🇯🇵の新しい研究成果「新型コロナウイルス変異株KP.3, LB.1, KP.2.3のウイルス学的特性の解明」について、プレプリント公開に先立って速報します。本研究では、最近いくつかの国で増加傾向にある、JN.1の子孫株である新しい3つの変異株の特性を検証しました。1/ 春になり、JN.1の子孫株が出現し、それらが優勢になり始めています。そのひとつ、KP.2 (JN.1.11.1.2)の特性については、すでにG2P-Japan🇯🇵が論文として報告しています。2/

https://x.com/G2PJapan/status/1793071831999766801

BREAKING🔔 Here I want to quickly report our new results from G2P-Japan🇯🇵 before the preprint publication. We have elucidated the virological characteristics of SARS-CoV-2 KP.3, LB.1 and KP.2.3 - progeny of JN.1. Please RT🔥 1/ Cf. A new one, KP.2 (JN.1.11.1.2), has been already elucidated. 2/

https://x.com/G2PJapan/status/1793071073006866929

#拡散希望 第2回新型コロナウイルス研究集会を、8月2日〜4日に東京・品川で開催します！　今年のテーマは「COVID-19の疫学、臨床医学、免疫学、ウイルス学」。新型コロナに関する科学のすべてを網羅した集会になるよう準備を進めています！ 1/
confit.atlas.jp/guide/event/co… 参加・演題登録はこちらから↓
今年は「オンデマンド配信」も予定しています。先約があったり、遠方で現地参加が難しい方や、医療従事者のみなさまにも広くご参加いただき、新型コロナの科学の最先端を知る機会を提供できればと思っています。2/
confit.atlas.jp/guide/event/co…

BREAKING🔔 A new study from G2P-Japan🇯🇵 is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 KP.2 - a progeny of JN.1. Please RT🔥 1/
biorxiv.org/cgi/content/sh… Cf. This is KP.2 (aka JN.1.11.1.2). In spike, KP.2 = JN.1 + S:R346T, S:F456L & S:V1104L).

We remember that R346T was observed in BQ.1.1 and XBB lineages, while F456L is a hallmark of EG.5 lineage. 2/

BREAKING🔔 The 32nd paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We show the breadth of antisera induced by XBB.1.5 monovalent vaccine - comparison between infection-naïve and XBB-infected individuals. Please repost🔥 1/
thelancet.com/journals/lanin… To control SARS-CoV-2 infection, the XBB.1.5 monovalent vaccine is now available. However, we found that natural infection with XBB subvariants, including XBB.1.5, does not efficiently induce humoral immunity against the infecting XBB subvariants, e.g. 2/

https://x.com/SystemsVirology/status/1701413583161266324?s=20

BREAKING🔔 The 33rd paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We elucidated the virological characteristics of SARS-CoV-2 JN.1 - a progeny of BA.2.86 (#Pirola). Please retweet/repost 1/
thelancet.com/journals/lanin… This is JN.1 (aka BA.2.86.1.1; in spike, JN.1 = BA.2.86 + S:L455S. We remember that the L455 substitution, S:L455F, was observed in the XBB lineage (e.g., HK.3 and these are known as "FLip" subvariants). 2/

#拡散希望 速報🔔 G2P-Japan🇯🇵の新しいプレプリント「JN.1のウイルス学的特性の解明」を、bioRxiv @biorxivpreprint に発表しました。本研究では、最近増加傾向にある、BA.2.86（俗称 #ピロラ）の子孫株である新しい変異株JN.1の特性を検証しました。1/
biorxiv.org/content/10.110… JN.1とは、S:L455Sという変異を獲得したBA.2.86の子孫株です。こんな変異を持っています。
JN.1 S = BA.2.86 S + S:L455Sです。2/

BREAKING🔔 A new study from G2P-Japan🇯🇵 is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 JN.1 - a progeny of BA.2.86 (#Pirola). Please RT🔥 1/
biorxiv.org/content/10.110… Cf. This is JN.1 (aka BA.2.86.1.1; in spike, JN.1 = BA.2.86 + S:L455S. Importantly, we remember that the L455 substitution, S:L455F, was observed in the XBB lineage (e.g., HK.3 and these are known as "FLip" subvariants). 2/

BREAKING🔔 A new study from G2P-Japan🇯🇵 is out! The preprint will be out so soon, but we first show our results on the efficacy of XBB.1.5 monovalent vaccine - comparison between infection-naïve and XBB-infected individuals. Please retweet/repost🔥 1/ XBB.1.5 monovalent mRNA vaccine has been available since September 2023. However, we found that breakthrough infection with XBB subvariants, including XBB.1.5, does not efficiently induce humoral immunity against the infecting XBB subvariants. e.g., 2/

https://x.com/SystemsVirology/status/1701413583161266324?s=20

#拡散希望 速報🔔 ちょっと遅れましたが、G2P-Japan🇯🇵の新しい研究成果「XBB.1.5単価ワクチンで誘導される中和抗体の機能の評価」を報告します。プレプリントは投稿中なので、近日中に公開されるかと思いますが、それに先立って速報します🔥 1/ 本年9月から、XBB.1.5対応単価ワクチンの接種が始まりました。期待を持たれるこのワクチンですが、我々の先行研究の結果を見ると、XBB亜株にブレイクスルー感染しても、XBBに対する中和抗体が充分に誘導されないことがわかっています。2/

https://x.com/SystemsVirology/status/1701408139978195165?s=20

BREAKING🔔 A new study from G2P-Japan🇯🇵 is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 BA.2.86 (aka #Pirola).
*BA.2.86 is has >30 mutations in the genome.
Please RT🔥 1/
biorxiv.org/content/10.110…


Epidemic dynamics modeling by @jampei2 and @JarelElgin showed that the relative effective reproduction number (Re) of BA.2.86 is 1.07-fold higher than that of the currently predominant EG.5.1, suggesting that BA.2.86 has the potential to become the next predominant one. 2/

BREAKING🔔 The 28th paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We elucidated the virological characteristics of new SARS-CoV-2 variant under monitoring, BA.2.86 (aka #Pirola). Please retweet/repost🔥 1/
thelancet.com/journals/lanin… Here I summarized the mutations detected in BA.2.86. 2/

BREAKING🔔 The 27th paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We elucidated the virological characteristics of new SARS-CoV-2 variant of interest, EG.5 (aka #Eris) Please RT🔥 1/
thelancet.com/journals/lanin… Currently, a subvariant of XBB.1.9, EG.5 (aka XBB.1.9.2.5) is well documented in Twitter (maybe aka #X) and elsewhere. 2/
* EG.5.1 S = XBB.1.9.2 S + #Q52H + #F456L
* XBB.1.9.2 S = XBB.1.5 S.

https://twitter.com/mvankerkhove/status/1688408370766663680?s=20

BREAKING🔔 A new study from G2P-Japan🇯🇵 is out! The preprint will be out so soon, but first we show our results on BA.2.86 - transmissibility, infectivity and immune resistance. This would be the 4th non-peer-reviewed🗒, but includes some new stuff. Please retweet/repost🔥 1/ Cf. Non-peer-reviewed works on BA.2.86:
The 1st🗒 from @yunlong_cao :


The 2nd🗒 from @BenjMurrell :


The 3rd🗒 from @BarouchLab :


Here I summarized the mutations detected in BA.2.86. 2/

https://twitter.com/yunlong_cao/status/1697318194976010446?s=20

https://twitter.com/BenjMurrell/status/1697751445351575656?s=20

https://twitter.com/BarouchLab/status/1698850719959544271?s=20